Abstract: The invention provides methods and compositions for detecting and/or quantifying modified nucleic acid oligonucleotides. These methods and compositions are useful for detecting and quantifying diagnostic and/or therapeutic synthetic modified oligonucleotides, such as aptamers, RNAi, siRNA, antisense oligonucleotides or ribozymes in a biological sample.

Abstract: Degradable blend of polycaprolactone and crystallization modifier especially suitable for use in the controlled release of biologically active proteins

Abstract: The invention relates to immunomodulatory compositions and related methods. The immunomodulatory compositions of a formula disclosed herein are useful for the prevention of sepsis and the treatment and prevention of diseases associated with inflammation and/or NOS.

Abstract: Modified nucleic acids are used for many purposes in research, diagnostic, and treatment protocols. However, direct sequencing of such molecules is generally considered to require special conditions. Methods of making a cDNA using a modified nucleic acid molecule and sequencing methods of sequencing a modified nucleic acid molecule are described.

Abstract: The invention provides compositions and methods for making and using sterically enhanced antagonist aptamer conjugates that include a nucleic acid sequence having a specific affinity for a target molecule and a soluble, high molecular weight steric group that augments or facilitates the inhibition of binding to, or interaction with, the target molecule binding partner by the target molecule when bound to the aptamer conjugate. The present invention also provides methods and formulations for ocular delivery of a biologically active molecule by attaching a charged moiety to the biologically active molecule and delivering the biologically active molecule by iontophoresis. Iontophoresis of a biologically active molecule that is conjugated to a high molecular weight neutral moiety, in enhanced by substituting the high molecular weight neutral moiety with a charged molecule of comparable size.

Abstract: The invention provides compositions and methods for making and using sterically enhanced antagonist aptamer conjugates that include a nucleic acid sequence having a specific affinity for a target molecule and a soluble, high molecular weight steric group that augments or facilitates the inhibition of binding to, or interaction with, the target molecule binding partner by the target molecule when bound to the aptamer conjugate. The present invention also provides methods and formulations for ocular delivery of a biologically active molecule by attaching a charged moiety to the biologically active molecule and delivering the biologically active molecule by iontophoresis. Iontophoresis of a biologically active molecule that is conjugated to a high molecular weight neutral moiety, in enhanced by substituting the high molecular weight neutral moiety with a charged molecule of comparable size.

Abstract: There is disclosed a cross-linked hyaluronate compound obtained by reacting a sodium hyaluronate compound with a polfunctional aziridine compound as a cross-linking agent. The polyfunctional aziridine compound was added to hyaluronan of various molecular weights in an equivalent ratio of HA/AZ of 1:1 to 1:10, preferably, 1:3 to 1:10, more preferably, 1:3 to 1:5; most preferably 1:4 to 1:5. The polymeric hydrogel compounds obtained are useful to prevent the formation of post-operative adhesions, designing tissue engineering applications, and the like.

Abstract: The invention relates to the field of drug delivery devices. More particularly, the invention relates to implantable, refillable drug delivery devices which provide for drug delivery over sustained time periods. The present invention has particular application for ophthalmic drug delivery applications.

Abstract: A biologically active conjugate is disclosed comprising a biopolymer and a therapeutic agent joined by a disulfide bond. The conjugate, when formulated in a pharmaceutical composition with a suitable carrier, has improved in vivo stability and activity, and can be targeted to a variety of cells, tissues and organs.

Abstract: A biologically active conjugate is disclosed comprising a biopolymer and a therapeutic agent joined by a disulfide bond. The conjugate, when formulated in a pharmaceutical composition with a suitable carrier, has improved in vivo stability and activity, and can be targeted to a variety of cells, tissues and organs.

Abstract: A water insoluble, biocompatible gel is prepared by reacting carboxymethylcellulose and a carbodiimide, wherein the reaction is conducted in an aqueous medium containing a water miscible organic solvent, such as a lower alkanol, an alkyl pyrrolidone, DMSO or acetone. The present method permits the reaction to contain higher concentrations of carboxymethycellylose and less carbodiimide than conventional methods.

Abstract: A biologically active conjugate is disclosed comprising a biopolymer and a therapeutic agent joined by a disulfide bond. The conjugate, when formulated in a pharmaceutical composition with a suitable carrier, has improved in vivo stability and activity, and can be targeted to a variety of cells, tissues and organs.

Abstract: Single phase gels for preventing the formation of surgical adhesions are disclosed. The gels are prepared by reacting an aqueous solution of a polyanionic polysaccharide, such as hyaluronic acid or carboxymethyl cellulose, with divinyl sulfone, to form a gel, the solution is neutralized, and a solid is precipitated from the solution. The solid can be redissolved in water to form a gel having properties which can be modified to suit a particular application.

Abstract: Degradable blend of polycaprolactone and crystallization modifier especially suitable for use in the controlled release of biologically active proteins